<DOC>
	<DOCNO>NCT00638469</DOCNO>
	<brief_summary>Adalimumab , fully human anti-tumor necrosis factor ( TNF ) monoclonal antibody approve treatment moderate severe psoriasis . However , portion case adalimumab induce reduction psoriasis area severity index ( PASI ) 75 % great , consider gold standard treatment efficacy . In study aim determine randomize half-side comparison whether additional narrowband UVB-311nm phototherapy accelerate improve clearance psoriatic lesion adalimumab-treated patient initial slow response .</brief_summary>
	<brief_title>UVB-311nm After Initial Slow Response Adalimumab Psoriasis</brief_title>
	<detailed_description>Patients moderate severe psoriasis receive treatment adalimumab ( load dose 80 mg thereafter 40 mg s.c. biweekly ) least 6 week without PASI reduction 75 % great qualify study . Adalimumab continue UVB-311nm phototherapy add 6 week thereafter one randomize body half ( left right ; head exempt ) 3 x per week complete response ( define reduction PASI &lt; 3 ) maximum another 6 week ( week 12 ) . PASI score , visual analogue score ( VAS ) patient score therapeutic response , VAS patient score severity skin lesion assess weekly ; follow-up visit month 3 , 6 , 12 . Paired Wilcoxon test difference PASI patient VAS score do ; Fischer exact test apply determine difference complete remission , PASI reduction &gt; 90 % , &gt; 75 % and/or 50 % body sit .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Psoriasis patient PASI reduction le 75 % least 6 week treatment adalimumab . Pregnancy lactation History skin cancer Presence history malignant skin tumor Dysplastic melanocytic nevus syndrome Antinuclear antibody ( dsDNA , Ro/SSA , La/SSB ) Autoimmune disorder Lupus erythematosus Dermatomyositis Photosensitive diseases porphyria , chronic actinic dermatitis , Xeroderma pigmentosum , basal cell nevus syndrome , others General poor health status</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Psoriasis</keyword>
	<keyword>Biologic</keyword>
	<keyword>adalimumab</keyword>
	<keyword>narrowband UVB</keyword>
	<keyword>phototherapy</keyword>
	<keyword>half-side comparison</keyword>
</DOC>